Biotech Startup Nkarta Therapeutics Raises $114 Million in Series B Financing
September 04 2019 - 12:28PM
Dow Jones News
By Colin Kellaher
Biotechnology startup Nkarta Therapeutics on Wednesday said it
raised $114 million in an oversubscribed Series B funding round at
an undisclosed valuation.
Nkarta, which is developing engineered natural killer cell
therapies to fight cancer, said new investor Samsara BioCapital led
the round.
New investors Amgen Inc.'s (AMGN) Amgen Ventures, Deerfield
Management, Life Science Partners, Logos Capital and RA Capital
Management also participated, joined by existing investors NEA
Ventures, SR One and Novo Holdings A/S, Nkarta said.
The South San Francisco, Calif., company, founded in 2015, said
it will use the funding to advance multiple programs into clinical
trials.
Nkarta, which previously raised $11 million in a Series A
financing, also said it expects to complete a manufacturing
facility in South San Francisco next year to supply investigational
product for its early-stage clinical trials.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 04, 2019 12:13 ET (16:13 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024